

Cambridge International Examinations

Cambridge International Advanced Subsidiary and Advanced Level

BIOLOGY 9700/23

Paper 2 AS Level Structured Questions

May/June 2016

MARK SCHEME
Maximum Mark: 60

Published

This mark scheme is published as an aid to teachers and candidates, to indicate the requirements of the examination. It shows the basis on which Examiners were instructed to award marks. It does not indicate the details of the discussions that took place at an Examiners' meeting before marking began, which would have considered the acceptability of alternative answers.

Mark schemes should be read in conjunction with the question paper and the Principal Examiner Report for Teachers.

Cambridge will not enter into discussions about these mark schemes.

Cambridge is publishing the mark schemes for the May/June 2016 series for most Cambridge IGCSE[®], Cambridge International A and AS Level components and some Cambridge O Level components.

® IGCSE is the registered trademark of Cambridge International Examinations.



Page 2	Mark Scheme	Syllabus	Paper
	Cambridge International AS/A Level – May/June 2016	9700	23

Mark scheme abbreviations:

; separates marking points

I alternative answers for the same point

R reject

A accept (for answers correctly cued by the question, or by extra guidance)

AW alternative wording (where responses vary more than usual)

<u>underline</u> actual word given must be used by candidate (grammatical variants accepted)

max indicates the maximum number of marks that can be given

ora or reverse argument

mp marking point (with relevant number)

ecf error carried forward

I ignore

Pa	age 3	3		yllabus	Paper
			Cambridge International AS/A Level – May/June 2016	9700	23
1	(a)	(i)	letter X written in space above cilia ; A label line into this space		[1]
		(ii)	nucleus;		[1]
		(iii)	cilia; columnar/tall/not flat/not thin; nuclei rounded/AW; presence of goblet cells;		[max 1]
	(b)	(i)	mitosis ;		[1]
		(ii)	<pre>presence of any 3 of: 1 shorter/no/fewer/damaged, cilia; A paralysed 2 undifferentiated/AW, cells; 3 flattened/squamous, cells/epithelium; 4 scar tissue; A scar tissue forms 5 enlarged goblet cells; 6 excess/accumulated/AW, mucus; A excess mucus secreted 7 tar deposits; A description of tar on lining 8 phagocytes; 9 AVP; e.g. inflammation (of bronchial lining)</pre>		
			Avi , c.g. illiammation (of biolicinal lilling)		[max 3]
					[Total: 7]
2	(a)	(i)	3.4 μ M min ⁻¹ ; A 3.4 μ M/min		[1]
		(ii)	0.15 mM ;; A ecf from (a) (i) allow 1 mark if no units given		
			if answer incorrect allow one mark for evidence of $\frac{1}{2}$ V_{max} 3.4/2 = 1.7		[2]
	(b)	max	x 3 if no attempt at description (D) with explanation (E)		
		at lo 1 2 3	(D) rate of reaction proportional to substrate concentration; AW (D) up to 0.25 mM; A range 0.25–0.30 mM (E) not all active sites occupied; A few, enzyme-substrate complexes/ES complexes/ESC		
		4	A more active site occupied as substrate concentration increases (E) substrate concentration is limiting;		
		5 6 7 8	igher substrate concentrations (D) less steep increase in rate (from 0.25 mM); (D) further increase in substrate concentration gives, no further increase plateau/levelling out, in rate; A rate remains at 3.4 μM min ⁻¹ (D) greater than/at, 0.45 mM; A 0.46 / 0.47, mM (E) enzyme concentration is limiting; A idea that some other factor is		
		9	(E) all active sites occupied / AW;(E) A for mp3/mp6 description in terms of enzyme-substrate collision context;	s in	[max 4]

Page 4	+	Mark Scheme	Syllabus	Paper
		Cambridge International AS/A Level – May/June 2016	9700	23
(c)	(i)	folding/coiling, (of polypeptide chain); tertiary structure; (held in position by) <i>ref. to</i> R group interactions; A two or more bond types in context brings distant, amino acids/parts of the chain, close; AW		[max 3]
	(ii)	water ; A H ₂ O		[1]
				[Total: 11]
				[Total. 11]
3 (a)	for	eign / AW ; A not from the person's own body gers / AW, an immune response/production of antibodies ; A other events in immune response described		
	pro	tigen tein/glycoprotein; A polysaccharide to, binding of specific antibody/formation of antigen-antibody comple	ЭΧ;	[max 3]
3 (b)	(i)	P antigen-binding site/site for antigen attachment; A variable regi	on	
		Q hinge region;		
		R constant region/site of attachment to receptors on phagocytes/A	۸W;	[3]
	(ii)	disulfide (bonds); R if more than one type of bond stated		[1]
(c)	(i)	 TNF-α/antigen, introduced into, mice/small mammals/named (antibody-producing), B-cells/B-lymphocytes/plasma cells/splisolated (from spleen); A produced fused with myeloma cells; using fusogen/PEG; hybridoma cells formed; ref. to screening/testing, for hybridoma producing desired antib 	enocytes,	
		 ref. to scaling up/large-scale production; AVP; e.g. HAT medium for, hybridoma growth/inhibiting myeld growth 	oma	[max 3]
	(ii)	antibodies bind to TNF- α ; inactivate/destroy TNF- α ; inflammation cannot be triggered/AW; in context of destroying TN	IF- α	[max 2]
				[Total: 12]

Mark Scheme

Syllabus

Paper

Page 4

Page 5	5	Mark Scheme	Syllabus	Paper
		Cambridge International AS/A Level – May/June 2016	9700	23
4 (a)	labe	el line to wall or lumen of any phloem sieve tube ;		[1
(b)	fron	asport of assimilates; A named assimilate e.g. sucrose/amino acids a source to sink; A from leaves to named sink e.g. roots/fruits aslocation/mass flow;	/auxins	[max 2
(c)	lign R p cell A h	in for, waterproofing; in, for support/to prevent (inward) collapse/AW (of vessel or plant); revent bursting I withstand (high) pressure ulose for, adhesion of water/formation of hydrogen bonds with water ydrophilic parts of lignin for lateral movement of water;		
	AVI	e.g. rings/spirals, for, extension/growth;		[max 3
(d)	(i)	surface area $(0.1 \times 0.1 \times 6 =) 0.06 \text{ (m}^2)$; volume $(0.1 \times 0.1 \times 0.1 =) 0.001 \text{ (m}^3)$; A 1×10^{-3} surface area to volume ratio $(0.06/0.001 =) 60$; A ecf using values given for surface area or vol	ume	[3
	(ii)	idea that diffusion (via, body surface/to cells), cannot satisfy needs/too slow or transport system delivers materials to cells more quickly; A efficient supply of, nutrients/oxygen, to all cells	,	
		long(er) distances (to reach some, cells/tissues); takes, materials/AW, close to cells;		[max 2
				[Total: 11
i (a)		parks if another mode of transmission given (e.g. faecal-oral/contact, unpasteurised milk/contaminated meat (M. bovis)	/sexual)	
	1	aerosol/droplet, infection;	0	
	2	only need to have one of 'infected'/'uninfected' to gain mp2 and mp infected/AW, person, coughs/breathes/spits/talks/sneezes; uninfected/AW, person, inhales/inspires/breathes in, droplets;)J	
	4	allow one mark if mp2 and mp3 given with no reference to, infected uninfected organism/pathogen/bacteria/ <i>M. tuberculosis</i> , in, airborne droplets in air; A without 'airborne ' or 'in air' if mp2 gained		[max 2
(b)	1	incomplete treatment/dose not finished;		

- (b) 1 incomplete treatment/dose not finished;
 - 2 not all bacteria killed/some bacteria survive ; R TB for bacteria
 - 3 <u>mutation</u>; **R** mutation to give immunity
 - 4 further detail of mutation;
 - 5 <u>selection</u> of resistant bacteria/resistant bacteria <u>selected</u> for ;
 - 6 resistant bacteria reproduce/vertical resistance;
 - 7 death of, susceptible/non-resistant, bacteria;
 - 8 AVP; e.g. horizontal resistance/described

[max 4]

Page (6	Mark Scheme	Syllabus	Paper
		Cambridge International AS/A Level – May/June 2016	9700	23
(c)	(i)	making/synthesis of, (m)RNA; from a DNA, template/sequence of bases/sequence of nucleotide A from a gene	s;	[2]
	(ii)	 idea that pathogen and human RNA polymerase are (slightly) different shaped active sites A rifampicin unable to, cross cell surface membrane/ente cross nuclear envelope 		[1]
(d)	1 2 3 4 5 6 7 8 9 10 11 12 13	prescribing/take, antibiotics, only when (absolutely) necessary; ensure, correct/effective, antibiotic(s) prescribed/used; complete course/follow instructions for use, of antibiotics; A ref. to patients to, use only antibiotics prescribed/not use leftover antibiotilater date/AW; ref. to monitoring situation to check if antibiotic is effective; use other antibacterials; develop new, drugs/antibiotics; ensure/improve, knowledge of, healthcare professionals/public; reduce/control, antibiotics in, agriculture/animals used for food; reporting patterns of antibiotic resistance/AW; ref. to breaking transmission cycle/described example; e.g. vaccinhygiene in hospitals break transmission cycle of resistant bacteria; e.g. quarantine AVP; e.g. WHO Global Plan Stop TB further detail of mp1 or mp2; e.g. only prescribe wide-spectrum and when narrow spectrum not known	ics at a	[max 3]
(e)	e.g	a that antibiotics act at a cell structure not possessed by a virus; viruses, do not have, a cell wall/a cell surface membrane/ribosom		
	anti A c	gestion that viruses, are inside host cells/not within reach(of antibion ibiotics act only on, living/growing, cells (viruses do not grow); an prevent metabolic processes not occurring in viruses ibiotics do not act on, protein coat/capsid/capsomeres/viral envelo	, .	Imay 21
	anu	ibiotics do not act on, protein coat/capsid/capsomeres/viral envelo	pe,	[max 2]
6 (a)	(su	perior/inferior) vena cava ;		[1]
(b)	A fu (left ref. puli	(ventricle) pumps blood to the body/right ventricle pumps blood to lurther distance to ventricle) requires higher pressure; ora to overcoming greater resistance/lungs less resistance; monary capillaries damaged by higher pressure; ner pressure requires more muscular force/AW; ora	ungs;	[max 3]
(c)	sind	patrial node ;		[1]
				[Total: 5]